Home › Diffuse Large B-Cell Lymphoma › New Jersey › Newark
Diffuse Large B-Cell Lymphoma clinical trials in Newark, NJ
3 studies for Diffuse Large B-Cell Lymphoma are looking for participants at sites in and around Newark (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
RecruitingPhase 3
- New Jersey Cancer Care ( Site 7002), Belleville · 4 mi away
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
RecruitingPhase 2
- Atlantic Health Morristown Medical Center ( Site 0163), Morristown · 17 mi away
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
RecruitingPhase 3
- Atlantic Health, Morristown · 17 mi away
Diffuse Large B-Cell Lymphoma trials in other cities
- New York City, NY20 studies
- Baldwin Park, CA19 studies
- Los Angeles, CA18 studies
- Houston, TX18 studies
- Chicago, IL18 studies
- Milwaukee, WI17 studies
- Nashville, TN17 studies
- Boston, MA17 studies
- Philadelphia, PA15 studies
- Durham, NC15 studies
- Portland, OR15 studies
- Cleveland, OH13 studies
Other studies in Newark
- Breast Cancer17 studies
- Spinal Cord Injuries14 studies
- Acute Myeloid Leukemia12 studies
- Metastatic Cancer10 studies
- Non-Small Cell Lung Cancer10 studies
- Heart Failure9 studies
- Pancreatic Cancer8 studies
- Melanoma8 studies
- Cardiovascular Disease8 studies
- Cancer (all types)7 studies
- Stroke7 studies
- Chronic Lymphocytic Leukemia7 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.